StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MRNABullishModerna Q3 2026 earnings and guidance raisenews
High materiality8/10

Moderna earnings analysis: questions answered and next catalysts

Nov 6, 2026, 1:32 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The company disclosed a one-quarter swing to profitability alongside an upward FY revenue outlook and a materially higher year-end cash target, implying stronger near-term revenue and cash-flow versus prior expectations; R&D cuts reduce near-term cash burn. Durability depends on Q4 demand and product launch cadence (e.g., flu and combination vaccines).

AI summary

What happened, with direct paths to the underlying reporting

Moderna reported Q3 2026 EPS of $0.38 and net income of $162M on $1.31B revenue, and raised FY2026 growth guidance to 15%–25% while boosting year-end cash guidance to $8.1–8.3B and trimming R&D guidance.

  • Q3 EPS was $0.38 (profit).
  • Revenue was $1.31B, up 29% year-over-year.
  • Net income was $162M versus a loss of $200M a year earlier.
  • FY2026 growth guidance rose to 15%–25% from a prior outlook of "up to 10%".
  • Year-end cash guidance increased to $8.1–8.3B from $4.7–5.2B.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event